Does Aurobindo Disclose Clonazepam Raw Material Suppliers?
Aurobindo Pharma, a major generic manufacturer of clonazepam (branded as Klonopin generics), does not publicly disclose specific suppliers for active pharmaceutical ingredients (APIs) or raw materials in regulatory filings or product inserts. Supply chains for controlled substances like clonazepam are often kept confidential due to regulatory scrutiny from the DEA and FDA, which monitor precursors to prevent diversion.
Which Companies Supply Clonazepam APIs Globally?
Key global suppliers of clonazepam API include:
- Hetero Drugs (India): Produces clonazepam API and has supplied Indian generics firms.
- Macs Pharma (India): Lists clonazepam as a manufactured API for export.
- Unichem Laboratories (India): Supplies clonazepam intermediates and API.
- Ami Lifesciences (India): Offers clonazepam API with DMF filings for US markets.
Indian firms dominate due to cost advantages, with many holding FDA-approved Drug Master Files (DMFs) for clonazepam API.[1][2]
Is Aurobindo Likely Sourcing from Indian Suppliers?
Aurobindo sources most APIs domestically from Indian vendors to control costs and ensure supply reliability. Potential suppliers to Aurobindo for clonazepam-like benzodiazepines include Hetero or Unichem, based on shared industry networks and Aurobindo's Telangana manufacturing hub proximity. No direct confirmation exists in public records, as supplier lists appear only in private audits or ANDA filings not fully accessible.[3]
What FDA Data Reveals About Clonazepam Supply Chains?
FDA's drug shortage database and Orange Book list Aurobindo as a clonazepam supplier but omit upstream API sources. DMF holders for clonazepam API (Type II) number around 15-20, mostly Indian, suggesting Aurobindo uses multiple to mitigate risks. Check FDA's DMF directory for latest filings.[4]
Regulatory Risks and Supply Disruptions for Clonazepam
Clonazepam is a DEA Schedule IV controlled substance, heightening scrutiny on raw material imports. Past FDA warnings to Indian API makers (e.g., for impurities) have disrupted supplies, forcing firms like Aurobindo to switch vendors. No active clonazepam shortages tied to raw materials as of 2024.[5]
Sources
[1]: DrugPatentWatch.com - API manufacturers overview
[2]: FDA DMF Database - Clonazepam DMF holders
[3]: Aurobindo Pharma Annual Report 2023 - Supply chain summaries
[4]: FDA Orange Book - ANDA approvals for clonazepam
[5]: FDA Drug Shortages - Current status